Executives from Pfizer confirmed this week that the company hopes to have an Omicron-specific vaccine shot ready for the general public by March.
“We already have begun work on a DNA template tailored to the sequence of Omicron, a critical step in the process of advancing a variant version of our vaccine if in fact we find one is needed,” a Pfizer spokesperson told FOX Business. “[We are] also manufacturing the variant vaccine at risk, as we did for Beta and Delta before.”
“The announcement comes after the pharmaceutical giant previously said it would be able to develop and produce a tailor-made vaccine against the omicron variant in roughly 100 days, subject to regulatory approval, in the event that a third dose of its current BNT162b2 vaccine is not found to protect against the Omicron variant or other future variants,” reports Fox News.
“Earlier this month, Pfizer and BioNTech received approval from the Food and Drug Administration to expand the emergency use authorization of its COVID-19 vaccine booster doses to individuals 12 years of age and older. The FDA also reduced the amount of time between administration of a second dose and booster dose from at least six months to at least five months,” adds Fox.
Read the full report here.